Insulet PODD U.S. — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Insulet in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Insulet’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Insulet's u.s. — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Insulet's U.S. — total revenue?
- Insulet (PODD) reported U.S. — total revenue of $518.8M in Q1 2026.
- How has Insulet's U.S. — total revenue changed year-over-year?
- Insulet's U.S. — total revenue increased by 24.5% year-over-year, from $416.6M to $518.8M.
- What is the long-term trend for Insulet's U.S. — total revenue?
- Over 4 years (2021 to 2025), Insulet's U.S. — total revenue has grown at a 27.5% compound annual growth rate (CAGR), from $738.9M to $1.95B.
- What does U.S. — total revenue mean?
- The total amount of money earned from sales within the United States.
- How do you interpret U.S. — total revenue?
- An increase indicates successful market penetration, higher patient adoption rates, or effective pricing strategies within the U.S. healthcare system, while a decrease may signal increased competition or market saturation.
- How does U.S. — total revenue compare across companies?
- Comparable to domestic revenue segments reported by other medical device manufacturers, often benchmarked against regional market growth rates.